From Hypothesis to Reimbursement: The Cancer Research That Reached Patients in 2026

Research institutions and cancer charities mark World Cancer Research Day every September 24, a designation built on one argument: cancer science needs sustained funding. That framing points at the money going in. The more revealing question is what comes out, and 2026 produced unusually clear answers. Approvals landed, assays won reimbursement, and response rates arrived from trials that were hypothetical two years ago.

The eight companies below come from the PRISM Biotech, Pharmaceuticals and MedTech indexes. They sit at four points along the path from laboratory to patient, and each reached a dated, documented milestone this year.

Finding It Earlier: Detection Moves to Parts Per Million

Cancer detection has changed units. The question is no longer only whether disease shows up on a scan, but whether a handful of tumor molecules can be counted in a tube of blood. Both companies here measure residual disease in parts per million, and both have convinced Medicare to pay for it.

• NeoGenomics (NASDAQ: NEO): Runs accredited clinical oncology laboratories doing cancer genetics and next-generation sequencing for providers and pharmaceutical partners. In July it launched PTEN IHC CDx, the first immunohistochemistry companion diagnostic the FDA has approved for prostate adenocarcinoma, paired with AstraZeneca’s TRUQAP. NeoGenomics puts the population at roughly 35,000 patients diagnosed each year with metastatic hormone-sensitive prostate cancer, of whom about one in four, or 8,750, carry PTEN-deficient tumors. In August, MolDX granted Medicare coverage to its RaDaR ST residual-disease assay for immunotherapy response monitoring, a third covered indication, with detection down to one part per million under study conditions. The commercial picture turned in the same window: second quarter revenue reached $202 million, up 11%, and net income of $2 million replaced a $45 million loss a year earlier. That swing deserves a qualifier: it includes an $11 million gain on extinguishment of debt, so the underlying quarter was not yet profitable.
• Personalis (NASDAQ: PSNL): Builds NeXT Personal, a tumor-informed circulating tumor DNA test tracking up to roughly 1,800 variants specific to each patient. In May it secured a fourth Medicare coverage decision, covering response monitoring during neoadjuvant therapy in stage II and III triple-negative and HER2-positive breast cancer, on the strength of the 227-patient PREDICT-DNA study. ASCO data in June showed 100% sensitivity for relapse during surveillance in colorectal cancer and a median limit of detection of 1.66 parts per million in the TRACERx lung cohort. Second quarter revenue rose 30% to $22.4 million as clinical test volume nearly tripled to 10,384 tests. One caveat belongs beside those numbers: Tempus AI agreed in July to acquire Personalis at $16.25 per share, structured as an all-stock transaction with an option for Tempus to pay cash for up to half the consideration, and Personalis withdrew financial guidance as a result.

Theranostics: Imaging and Treating Through the Same Target

Radiopharmaceuticals sit in an unusual position because one targeting molecule can carry either a diagnostic isotope or a therapeutic one. Find the tumor with the first, treat it with the second. That pairing is why the field consolidated so fast this year.

• Telix Pharmaceuticals (NASDAQ: TLX, ASX: TLX): Commercializes the PSMA-PET prostate imaging agents Illuccix and Gozellix, the core of its oncology franchise. On September 14 the FDA approved Pixclara for PET imaging that distinguishes recurrent or progressive glioma from treatment-related change, in adults and in children from one month of age. The approval came the long way around, following a complete response letter in April 2025 and a resubmission in March 2026. Telix puts the US glioma population at roughly 24,000 new cases a year. Twelve days before the approval it completed enrollment in the Phase 3 BiPASS study of pre-biopsy prostate imaging, at 350 patients across the United States and Australia. First half revenue reached US$477 million, up 22% year over year, with US$251.9 million in cash at June 30, 2026.
• Perspective Therapeutics (NYSE American: CATX): Develops alpha-particle therapies on a lead-212 platform, with three assets in the clinic across somatostatin-receptor-positive neuroendocrine tumors, melanocortin-1-receptor-positive melanoma and FAP-alpha-positive solid tumors. Its second quarter update reported 76 neuroendocrine tumor patients treated across four dose cohorts of lead candidate VMT-alpha-NET as of July 31, with Phase 3 site activation targeted around the end of 2026, subject to regulatory feedback. Cash and short-term investments of $236.9 million at June 30, 2026 fund planned operations into late 2027 on the company’s own estimate.

Precision Therapeutics: Exploiting What the Tumor Already Lost

The most interesting recent oncology chemistry does not attack a tumor directly. It finds a gene the cancer has already deleted, then turns the consequence of that loss into a vulnerability the drug can exploit. Healthy tissue never lost the gene, so it survives the same drug, which is what makes the approach selective.

• Tango Therapeutics (NASDAQ: TNGX): Works on synthetic lethality. Lead candidate vopimetostat is an MTA-cooperative PRMT5 inhibitor built to kill cancers that have deleted the MTAP gene while sparing normal cells; the company puts MTAP deletion at 10% to 15% of all human cancers. In June, combining it with Revolution Medicines’ daraxonrasib in previously treated MTAP-deleted, RAS-mutant pancreatic cancer produced an objective response rate of 92%, 11 responses among 12 evaluable patients with nine confirmed at data cutoff, alongside 100% disease control. A $600 million offering the next day lifted cash to $1.0 billion at June 30, 2026. The data goes to ESMO in Madrid in late October. Tango also discontinued its TNG260 program in May and halted spending on TNG961.
• ALX Oncology (NASDAQ: ALXO): Makes evorpacept, which blocks CD47, the signal tumors use to tell macrophages not to consume them. A May readout combining it with zanidatamab in advanced HER2-positive breast cancer showed a 33% confirmed response rate across 24 patients, but the biomarker split is the real finding: among patients with centrally confirmed CD47 status, high expression produced responses in five of five, against one of four in the low-expression group, with median progression-free survival of 22.1 months versus 3.4 months. The rest of the program went the other way. ALX paused its ASPEN-CRC colorectal study in August 2025 to extend cash runway, and its head and neck trials, ASPEN-03 and ASPEN-04, missed their primary endpoints, after which the company said it would not pursue evorpacept with PD-1 inhibitors at this time. Development narrowed to the ASPEN-09-Breast study, where the protocol was amended so the primary endpoint reads out by CD47 expression and enrollment expanded from 80 to as many as 120 patients, with topline data from the first 80 expected in mid-2027. Cash of $153.4 million at June 30, 2026 funds operations through the first half of 2028 on its own estimate.

Treating Locally: Keeping the Dose Where the Tumor Is

Systemic toxicity sets the ceiling on many cancer therapies. Confine the dose to one organ, or deliver it without an incision, and the ceiling moves. Both companies here sell approved products rather than candidates, which makes their evidence commercial as well as clinical.

• Delcath Systems (NASDAQ: DCTH): Sells the HEPZATO KIT, which delivers high-dose melphalan straight to the liver by percutaneous hepatic perfusion, isolating the organ and filtering the blood before it returns to circulation. It is approved for adults with uveal melanoma and unresectable liver metastases affecting less than half the liver, with no extrahepatic disease or only limited extrahepatic disease amenable to resection or radiation. Second quarter revenue reached $29.1 million, up 20%, at a 90% gross margin, and full year guidance rose to between $104 million and $108 million. In July the company dosed its first patient in DELUMA, a Phase 2 study in liver-dominant metastatic HER2-negative breast cancer. The label carries a boxed warning, and the product moves only through a restricted REMS program, which governs how fast new centers can open.
• Profound Medical (NASDAQ: PROF, TSX: PRN): Manufactures TULSA-PRO, which uses MRI-guided transurethral ultrasound to ablate prostate tissue without an incision, with imaging confirming the treated region in real time. Humana became the first national US payer to cover the procedure, part of roughly 8.5 million covered lives added in the first quarter. In July the 211-patient CAPTAIN trial reported no median change in penile length one month after the TULSA procedure, against a median reduction of 0.65 centimeters after robotic radical prostatectomy. Revenue stays lumpy, though. Second quarter revenue grew 12% to US$2.5 million after roughly $3.1 million of shipments slipped into the third quarter, against $5.3 million in the first quarter. Absent that timing shift the figure would have been about $5.6 million. Full year guidance holds at approximately $25 million, on $38.3 million of cash.

What the Year Actually Proved

Read together, these eight describe one shift. The binding constraint has moved away from whether a mechanism works and toward whether a payer will fund it and a patient can reach it. NeoGenomics and Personalis spent 2026 collecting coverage decisions rather than chasing novelty. Profound’s case now rests on coverage as much as clinical data, with Humana the first national payer on board. Delcath’s limit is how fast certified centers open, not whether the drug reaches the tumor. Underneath that, biomarker selection is doing more work than mechanism. ALX Oncology’s response rate quadrupled once patients were sorted by CD47 expression, and Tango’s entire approach rests on a deletion the tumor performed on itself. Neither drug got better. The questions asked of them got sharper.

The caution is consolidation. Tempus AI is buying Personalis, and Telix agreed in September to merge with ITM Isotope Technologies Munich, the German therapeutic isotope manufacturer, for roughly US$1.65 billion upfront plus up to US$700 million in milestones. Scale is becoming the price of competing, which rewards the companies that reached commercial evidence first and squeezes the ones still funding trials from the equity market. Several names above remain pre-revenue and dependent on the next raise, so the cash positions cited here belong alongside the clinical results.

This article is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. PRISM MarketView is not a registered investment advisor. Companies mentioned are constituents of PRISM indexes; inclusion in an index does not imply endorsement. The clinical-stage and commercial-stage companies discussed carry significant regulatory, clinical, and financial risk, including the possibility of delay, non-approval, or commercial failure. Information is sourced from public filings and reports believed to be reliable but is not guaranteed to be accurate or complete. Readers should conduct their own research and consult a qualified financial advisor before making investment decisions. Past performance is not indicative of future results.